[EN] SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS<br/>[FR] PYRIDINYL-PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012101013A1
公开(公告)日:2012-08-02
The invention relates to new substituted pyridinyl-pyrimidines of formula 1 wherein ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O, wherein R1, R2, R4, R3, R5 and R6 are defined as in claim 1 and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.
INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
申请人:PFIZER INC.
公开号:EP1483268A2
公开(公告)日:2004-12-08
US8772305B2
申请人:——
公开号:US8772305B2
公开(公告)日:2014-07-08
[EN] INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS, AND METHODS FOR THEIR USE<br/>[FR] DERIVES INDOLYL-UREE DE THIENOPYRIDINES UTILISES COMME AGENTS ANTIANGIOGENIQUES, ET LEURS METHODES D'UTILISATION
申请人:PFIZER
公开号:WO2003074529A2
公开(公告)日:2003-09-12
The invention relates to compounds represented by the formula FI and to prodrugs thereof, pharmaceutically acceptable salts or solvates of said compounds or said prodrugs, wherein X, R1 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula I.
SUBSTITUTED PYRIDINYL-PYRIMIDINES AND THEIR USE AS MEDICAMENTS
申请人:Dahmann Georg
公开号:US20130023502A1
公开(公告)日:2013-01-24
The invention relates to new substituted pyridinyl-pyrimidines of formula
1
wherein
ring A is a five-membered saturated or unsaturated carbocyclic ring which optionally comprises one, two or three heteroatoms each independently from each other selected from the group N, S and O,
wherein R
1
, R
2
, R
4
, R
3
, R
5
and R
6
are defined as in claim
1
and wherein ring A is further optionally substituted by one or two further substituents and the pharmaceutically acceptable salts, diastereomers, enantiomers, racemates, hydrates and solvates of the aforementioned compounds.